NASDAQ:ABSI - Nasdaq - US00091E1091 - Common Stock - Currency: USD
ABSCI CORP
NASDAQ:ABSI (1/24/2025, 6:20:55 PM)
After market: 4.01 +0.01 (+0.25%)4
-0.17 (-4.08%)
The current stock price of ABSI is 4 USD. In the past month the price increased by 36.52%. In the past year, price increased by 7.82%.
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Get insights into the top gainers and losers of Wednesday's pre-market session.
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses deep learning AI and synthetic biology to expand proteins’ therapeutic potential. The rapid growth of artificial intelligence/machine learning (AI/ML) has led to the emergence of numerous companies that are difficult to tell apart. This challenge is worsened by the fact that clinical proof of concept (POC) in this area is still years away. Recently, Absci entered into a s
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 15.84 | 300.94B | ||
AMGN | AMGEN INC | 14.33 | 148.05B | ||
GILD | GILEAD SCIENCES INC | 21.01 | 115.99B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 862 | 113.22B | ||
REGN | REGENERON PHARMACEUTICALS | 14.88 | 74.26B | ||
ARGX | ARGENX SE - ADR | N/A | 38.80B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.95B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.47B | ||
ONC | BEIGENE LTD-ADR | N/A | 23.64B | ||
NTRA | NATERA INC | N/A | 22.13B | ||
BIIB | BIOGEN INC | 8.95 | 21.30B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.52B |
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 155 full-time employees. The company went IPO on 2021-07-22. The firm combines AI with scalable wet lab technologies to create biologics for patients. The company has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The firm uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The firm supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. The company reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.
ABSCI CORP
18105 Se Mill Plain Blvd
Vancouver Washington WASHINGTON US
CEO: Sean McClain
Employees: 155
Company Website: https://www.absci.com/
Investor Relations: https://investors.absci.com/
Phone: 13609491041
The current stock price of ABSI is 4 USD.
The exchange symbol of ABSCI CORP is ABSI and it is listed on the Nasdaq exchange.
ABSI stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ABSI, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ABSI.
ABSI does not pay a dividend.
ABSI does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.93).
The outstanding short interest for ABSI is 17.04% of its float.
ChartMill assigns a technical rating of 4 / 10 to ABSI. When comparing the yearly performance of all stocks, ABSI turns out to be only a medium performer in the overall market: it outperformed 51.37% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ABSI. The financial health of ABSI is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ABSI reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 19.48% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -41.52% | ||
ROE | -48.51% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 81% to ABSI. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 22.54% and a revenue growth -4.96% for ABSI